Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness Wire • 11/25/25
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta TherapeuticsBusiness Wire • 11/24/25
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1Business Wire • 11/24/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPRNewsWire • 11/20/25
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety WarningsZacks Investment Research • 11/17/25
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical SignificanceBenzinga • 11/04/25
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/04/25
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/04/25
Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's successMarket Watch • 11/03/25
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory TestsInvestors Business Daily • 11/03/25
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCEBusiness Wire • 11/03/25